Literature DB >> 34779991

Identification of 1β,2α-epoxytagitinin C as a Notch inhibitor, oxidative stress mechanism and its anti-leukemia activity.

Yoshinori Makita1,2, Shun Saito1, Anna Tsuchiya2, Masami Ishibashi2, Midori A Arai3.   

Abstract

Notch signaling plays crucial roles in cell differentiation and proliferation, but aberrant activation of this signaling results in tumorigenesis and cancer progression. Notch signaling is thus a promising drug target for oncotherapy, and the development of Notch signaling inhibitors is eagerly awaited. Notch inhibitory activity-guided fractionation of a Spilanthes acmella extract led to the identification of five sesquiterpene lactones: tagitinin A (1), 1β,2α-epoxytagitinin C (2), tagitinin C (3), orizabin (4), and 2α-hydroxytirotundin (5). 1β,2α-Epoxytagitinin C (2) exhibited Notch signaling inhibition, with an IC50 of 25.6 μM, and was further evaluated for its activity against HPB-ALL, a Notch-activated leukemia cell line. Compound 2 showed potent cytotoxicity against HPB-ALL (IC50 1.7 μM) and arrested the cell cycle at the G2/M phase, but did not induce apoptotic cell death. Notch inhibitory mechanism analysis suggested that compound 2 transcriptionally suppresses Notch1 mRNA. In addition, we found that oxidative stress induction is critical for Notch signaling inhibition and the cytotoxicity of compound 2. This is the first mechanism of small molecule Notch inhibition. Our results demonstrate that 1β,2α-epoxytagitinin C (2) is a potential anti-leukemia agent and further investigation of this compound is warranted.
© 2021. The Japanese Society of Pharmacognosy.

Entities:  

Keywords:  Notch signaling; Oxidative stress; Sesquiterpene lactones; Tagitinin

Mesh:

Year:  2021        PMID: 34779991     DOI: 10.1007/s11418-021-01584-0

Source DB:  PubMed          Journal:  J Nat Med        ISSN: 1340-3443            Impact factor:   2.343


  38 in total

1.  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors:  Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal:  Science       Date:  2004-10-08       Impact factor: 47.728

Review 2.  Notch signaling: an emerging therapeutic target for cancer treatment.

Authors:  Xun Yuan; Hua Wu; Hanxiao Xu; Huihua Xiong; Qian Chu; Shiying Yu; Gen Sheng Wu; Kongming Wu
Journal:  Cancer Lett       Date:  2015-09-01       Impact factor: 8.679

3.  The Notch meeting: an odyssey from structure to function.

Authors:  Ajay Chitnis; Laure Balle-Cuif
Journal:  Development       Date:  2016-02-15       Impact factor: 6.868

Review 4.  The Notch signaling pathway: transcriptional regulation at Notch target genes.

Authors:  T Borggrefe; F Oswald
Journal:  Cell Mol Life Sci       Date:  2009-05       Impact factor: 9.261

Review 5.  Notch signaling: simplicity in design, versatility in function.

Authors:  Emma R Andersson; Rickard Sandberg; Urban Lendahl
Journal:  Development       Date:  2011-09       Impact factor: 6.868

Review 6.  Therapeutic modulation of Notch signalling--are we there yet?

Authors:  Emma R Andersson; Urban Lendahl
Journal:  Nat Rev Drug Discov       Date:  2014-05       Impact factor: 84.694

Review 7.  The Canonical Notch Signaling Pathway: Structural and Biochemical Insights into Shape, Sugar, and Force.

Authors:  Rhett A Kovall; Brian Gebelein; David Sprinzak; Raphael Kopan
Journal:  Dev Cell       Date:  2017-05-08       Impact factor: 12.270

Review 8.  Notch signalling in solid tumours: a little bit of everything but not all the time.

Authors:  Prathibha Ranganathan; Kelly L Weaver; Anthony J Capobianco
Journal:  Nat Rev Cancer       Date:  2011-04-14       Impact factor: 60.716

Review 9.  Notch signaling: switching an oncogene to a tumor suppressor.

Authors:  Camille Lobry; Philmo Oh; Marc R Mansour; A Thomas Look; Iannis Aifantis
Journal:  Blood       Date:  2014-03-07       Impact factor: 22.113

10.  A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumors.

Authors:  Toshihiko Doi; Masaomi Tajimi; Joji Mori; Hiroya Asou; Koichi Inoue; Karim A Benhadji; Yoichi Naito
Journal:  Invest New Drugs       Date:  2020-09-16       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.